sabatolimab   Click here for help

GtoPdb Ligand ID: 12361

Synonyms: MBG-453 | MBG453
Compound class: Antibody
Comment: Sabatolimab (MBG-453) is an anti-TIM3 (HAVCR2) monoclonal antibody [1-2], that was developed as a leukemia immunotherapy. It binds to TIM3 on myeloid cells, blocking the interaction between TIM3 and its endogenous ligands PtdSer/galectin 9. This action blocks TIM3's function as an immune co-inhibitory receptor, and promotes an immune response against neoplastic myeloid cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Barth S, Naran K. (2022)
TIM-3: a tumor-associated antigen beyond checkpoint inhibition?.
Immunother Adv, 2 (1): ltac021. [PMID:36406467]
2. Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, Baker L, Velez J, Ramesh R, Wavreille AS et al.. (2022)
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Immunother Adv, 2 (1): ltac019. [PMID:36196369]